Aguado T, Romero E, Monory K, Palazuelos J, Sendtner M, et.al. (2007). The CB1 cannabinoid
receptor mediates excitotoxicity-induced neural progenitor proliferation and neurogenesis.
J Biol Chem., 282(33), 23892-8.
Alger BE. (2004). Endocannabinoids and their implications for epilepsy. Epilepsy
Curr., 4(5), 169-73.
Benito,C., Nunez, E., Tolo, R.M., Carrier, E.J., Rabano, A., et.al. (2003). Cannabinoid
CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic
plaque-associated glia in Alzheimer�s Disease brains. J. Neurosci, 23(35),11136
�11141.
Benito C, Romero JP, Tol�n RM, Clemente D, Docagne F, et.al. (2007). Cannabinoid
CB1 and CB2 receptors and fatty acid amide hydrolase are specific markers of plaque
cell subtypes in human multiple sclerosis. J Neurosci., 27(9),
2396-402.
Benito, C., Tolon, R.M., Pazos, M.R., Nunez, E., Castillo, A.I., et al. (2008).
Cannabinoid CB2 receptors in human brain inflammation. Br. J. Pharmacol.
153 (2), 277�285.
Campbell VA & Gowran A. (2007). Alzheimer's disease; taking the edge off with
cannabinoids?
Br J Pharmacol., 152(5),655-62.
Centonze, D., Finazzi-Agro, A., Bernardi, G., & Maccarrone, M. (2007). The endocannabinoid
system in targeting inflammatory neurodegenerative diseases. Trends Pharmacol Sci,
28(4) 180-187.
Chen J, Lee CT, Errico SL, Becker KG, &Freed WJ. (2007). Increases in expression of 14-3-3 eta and 14-3-3 zeta transcripts during neuroprotection
induced by delta9-tetrahydrocannabinol in AF5 cells. J Neurosci Res.,
85(8), 1724-33.
Chen J, Lee CT, Errico S, Deng X, Cadet JL, & Freed WJ. (2005). Protective effects
of Delta(9)-tetrahydrocannabinol against N-methyl-d-aspartate-induced AF5 cell death.
Brain Res Mol Brain Res.,134(2), 215-25.
Ehrhart, J., Obregon, D., Mori, T., Hou, H., Sun, N., et.al. (2005). Stimulation
of cannabinoid receptor 2 (CB2) suppresses microglial activation. J. Neuroinflam.,
2(29), doi:10.1186/1742-2094-2-29.
El-Remessy AB, Khalil IE, Matragoon S, Abou-Mohamed G, Tsai NJ, et.al. (2003). Neuroprotective
effect of (-)Delta9-tetrahydrocannabinol and cannabidiol in N-methyl-D-aspartate-induced
retinal neurotoxicity: involvement of peroxynitrite. Am J Pathol.,
163(5), 1997-2008.
Eubanks, L.M., Rogers, C.J., Beuscher IV, A.E., Koob, G.F., Olson, A.J., et.al.
(2006). A molecular link between the active component of marijuana and Alzheimer�s
Disease pathology. Mol. Pharm. 3(6) 773-777.
Karanian DA, Brown QB, Makriyannis A, Kosten TA, & Bahr BA. (2005). Dual modulation
of endocannabinoid transport and fatty acid amide hydrolase protects against excitotoxicity.
J Neurosci., 25(34), 7813-20.
Kim SH, Won SJ, Mao XO, Ledent C, Jin K, & Greenberg DA. (2006). Role for neuronal
nitric-oxide synthase in cannabinoid-induced neurogenesis. J Pharmacol Exp Ther.,
319(1), 150-4.
Kim SH, Won SJ, Mao XO, Jin K, & Greenberg DA. (2005). Involvement of protein
kinase A in cannabinoid receptor-mediated protection from oxidative neuronal injury.
J Pharmacol Exp Ther., 313(1):88-94.
Leker RR, Gai N, Mechoulam R, & Ovadia H. (2003). Drug-induced hypothermia reduces
ischemic damage: effects of the cannabinoid HU-210. Stroke, 34(8), 2000-6.
Mach F, Montecucco F, & Steffens S. (2008). Cannabinoid receptors in acute and
chronic complications of atherosclerosis. Br J Pharmacol., 153(2), 290-8.
Malfait, A. M., Gallily, R., Sumariwalla, P. F., Malik, A. S., Andreakos, E., Mechoulam,
R., et al. (2000). The nonpsychoactive cannabis constituent cannabidiol is an oral
anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad
Sci U S A, 97(17), 9561-9566.
Mechoulam R, & Hanu L. (2001). The cannabinoids: an overview. Therapeutic implications
in vomiting and nausea after cancer chemotherapy, in appetite promotion, in multiple
sclerosis and in neuroprotection. Pain Res Manag., 6(2), 67-73.
Palazuelos J, Davoust N, Julien B, Hatterer E, Aguado T, et.al (2008). The CB(2)
cannabinoid receptor controls myeloid progenitor trafficking: involvement in the
pathogenesis of an animal model of multiple sclerosis. J Biol Chem. 283(19), 13320-9.
Pryce G, Ahmed Z, Hankey DJ, Jackson SJ, Croxford JL, et.al. (2003). Cannabinoids
inhibit neurodegeneration in models of multiple sclerosis. Brain,
126(10), 2191-202.
Ram�rez BG, Bl�zquez C, G�mez del Pulgar T, Guzm�n M, & de Ceballos ML. (2005).
Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated
by blockade of microglial activation. J Neurosci. 25(8), 1904-13.
Sagredo, O., Garc�a-Arencibia, M., de Lago, E., Finetti, S., Decio, A., et.al (2007).
Cannabinoids and Neuroprotection in basal ganglia disorders. Mol Neurobiol,
36(1), 82�91
Shouman B, Fontaine RH, Baud O, Schwendimann L, Keller M, et.al. (2006). Endocannabinoids
potently protect the newborn brain against AMPA-kainate receptor-mediated excitotoxic
damage. Br J Pharmacol., 148(4), 442-51.
Sun Y, Alexander SP, Garle MJ, Gibson CL, Hewitt K, et.al. (2007). Cannabinoid activation of PPAR alpha; a novel neuroprotective mechanism.
Br J Pharmacol. 152(5), 734-43.
van der Stelt M, Veldhuis WB, B�r PR, Veldink GA, Vliegenthart JF, et.al. (2001).
Neuroprotection by Delta9-tetrahydrocannabinol, the main active compound in marijuana,
against ouabain-induced in vivo excitotoxicity. J Neurosci.,21(17), 6475-9.
Walther, S., Mahlberg, R., Eichmann,U. & Kunz, D. (2006). Delta-9-tetrahydrocannabinol
for nighttime agitation in severe dementia. Psychopharmacol 185(4), 524�528.
Witting A, Chen L, Cudaback E, Straiker A, Walter L, et.al. (2006). Experimental
autoimmune encephalomyelitis disrupts endocannabinoid-mediated neuroprotection.
Proc Natl Acad Sci U S A., 103(16), 6362-7.
Zani A, Braida D, Capurro V, & Sala M. (2008). Delta9-tetrahydrocannabinol (THC)
and AM 404 protect against cerebral ischaemia in gerbils through a mechanism involving
cannabinoid and opioid receptors. Br J Pharmacol. 152(8), 1301-11.
Zhang M, Martin BR, Adler MW, Razdan RK, Ganea D, et.al. (2008). Modulation of the
balance between cannabinoid CB(1) and CB(2) receptor activation during cerebral
ischemic/reperfusion injury. Neurosci.,152(3), 753-60.